motixafortide

Term ID

CHEBI:145536

Synonyms

(3S,6S,9S,12R,17R,20S,23S,26S,29R,34aS)-26,29-bis(4-aminobutyl)-N-[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]-17-{[(2S)-2-{[(2S)-5-carbamimidamido-2-{[(2S)-5-carbamimidamido-2-(4-fluorobenzamido)pentanoyl]amino}pentanoyl]amino}-3-(naphthalen-2-yl)pr
4F-benzoyl-TN14003
BKT 140
BKT-140
BKT140
BL 8040
BL-8040
BL8040
motixafortida
motixafortide
motixafortidum
TF 14016
TF-14016
TF14016
TN-14003

Definition

A heterodetic cyclic peptide that has antineoplastic activity. It is a CXC chemokine receptor 4 (CXCR4) antagonist with an IC50 value of 0.8 nM and is currently under clinical investigation for the treatment of hematological malignancies, solid tumors, and stem cell mobilization. It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer in 2019.

References

Ontology

ChEBI ( EBI )

Relationships

is a type of: heterodetic cyclic peptide

heterodetic cyclic peptide Show first 5 Terms
has_role: antineoplastic agent apoptosis inducer C-X-C chemokine receptor type 4 antagonist

antineoplastic agent apoptosis inducer C-X-C chemokine receptor type 4 antagonist Show first 5 Terms
inverse has_part: motixafortide acetate

motixafortide acetate Show first 5 Terms

Phenotype

Phenotype resulting from motixafortide

Phenotype where environments contain motixafortide

Phenotype modified by environments containing motixafortide

Human Disease Model